GLP-1 dosing guide: escalation, timing, and what affects your dose. - Reddit

What GLP-1 receptor agonists are

Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the naturally occurring incretin hormone GLP-1, which the gut secretes in response to food. Activated GLP-1 receptors in the pancreas, brain, and GI tract work together to reduce appetite, slow gastric emptying, and support blood sugar regulation.

Compounded semaglutide is a GLP-1 receptor agonist. Compounded tirzepatide is a dual agonist—it activates both GLP-1 receptors and GIP (glucose- dependent insulinotropic polypeptide) receptors, which together produce a more pronounced effect on appetite and weight management than GLP-1 activation alone.

Both are compounded by licensed 503A pharmacies in the United States for individual patients with a valid prescription. They are not FDA-approved drugs. No hidden overseas supply chain.

Why does GLP-1 dosing require slow escalation instead of starting at a higher dose?

The GLP-1 receptors in the gut that govern gastric motility are especially sensitive to rapid dose changes. When GLP-1 receptor activity increases too quickly, the most common result is a cluster of GI effects: nausea, vomiting, diarrhea, constipation, and a feeling of fullness so intense that eating becomes difficult.

Slow escalation—four weeks at each dose step before advancing— gives the GI tract time to adapt while still allowing the hypothalamic appetite-suppression effects to accumulate. Patients who rush escalation are also the most likely to discontinue because of side effects, which means they never reach the dose where meaningful benefit occurs.

Compounded semaglutide: typical dose escalation

The dose escalation schedule for compounded semaglutide in a clinician- supervised weight management program typically follows this structure (doses and timing are always clinician-determined and patient-specific):

• Month 1: 0.25 mg subcutaneously once weekly. The initiating dose is intentionally low. Its purpose is tolerability testing, not weight management effect.
• Month 2: 0.5 mg once weekly, if month 1 was tolerated. The first dose at which some patients begin to notice appetite suppression.
• Month 3: 1 mg once weekly. Many patients see meaningful weight trajectory changes begin here.
• Month 4 onward: 1.7 mg and 2.4 mg, each held for four weeks pending tolerability. Some patients achieve their goals at 1 mg or 1.7 mg and never need to escalate further.

These are reference steps. A clinician may hold any dose longer, reduce it, or adjust frequency based on your individual response.

Compounded tirzepatide: typical dose escalation

Tirzepatide’s dual mechanism produces more pronounced effects at equivalent early doses compared to semaglutide, and the dose escalation is correspondingly structured in larger increments over longer intervals. Standard clinician-supervised escalation looks like:

• Weeks 1–4: 2.5 mg subcutaneously once weekly.
• Weeks 5–8: 5 mg, if 2.5 mg was well tolerated.
• Weeks 9–12: 7.5 mg. A dose at which many patients see substantial weight management progress.
• Weeks 13–20: 10 mg and 12.5 mg in four-week increments if escalation continues.
• Maintenance: Up to 15 mg once weekly. Not every patient needs this dose to achieve their goals.

What makes your GLP-1 dose different from someone else’s

Two patients starting compounded semaglutide on the same day may be prescribed entirely different escalation paths. Here’s why:

GI tolerability

Your gut’s response at each dose step is the primary determinant of when escalation happens. A patient who experiences significant nausea at 0.5 mg may stay there for eight weeks before moving to 1 mg. A clinician who is not tracking your GI response cannot make that call safely.

Starting weight and metabolic baseline

Your starting BMI, baseline blood glucose, and lipid panel inform not just starting dose but long-term dose targets. Patients with a higher degree of insulin resistance may respond differently at a given dose than those without it.

Concomitant medications

GLP-1 agents slow gastric emptying. For patients on oral medications with narrow therapeutic windows—anticoagulants, thyroid hormones, some cardiac drugs—that slowed absorption changes the pharmacokinetics of those drugs. Your prescribing clinician needs your full medication list before setting a GLP-1 dose.

Contraindications

Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2) are contraindicated for GLP-1 receptor agonists. A history of pancreatitis is a relative contraindication that requires careful clinical review. These are not things a dosing calculator asks about.

Injection technique and timing

Compounded semaglutide and tirzepatide are administered as subcutaneous injections—into the fatty tissue of the abdomen, thigh, or upper arm. Rotating injection sites prevents localized skin reactions. Consistent weekly timing helps maintain stable plasma drug levels; the same day each week is easiest to track.

Storage matters: compounded peptide formulations should be refrigerated and protected from light. Always follow the storage instructions that accompany your prescription.

If you have never self-administered an injection, the intake assessment includes a clinical review, and your prescribing clinician can walk you through technique guidance or direct you to a resource that does.

Frequently asked questions